97 related articles for article (PubMed ID: 25489883)
1. Cytochrome P450-Mediated Biotransformation of Sorafenib and Its N-Oxide Metabolite: Implications for Cell Viability and Human Toxicity.
Gillani TB; Rawling T; Murray M
Chem Res Toxicol; 2015 Jan; 28(1):92-102. PubMed ID: 25489883
[TBL] [Abstract][Full Text] [Related]
2. Differential effects of hepatic cirrhosis on the intrinsic clearances of sorafenib and imatinib by CYPs in human liver.
Murray M; Gillani TB; Ghassabian S; Edwards RJ; Rawling T
Eur J Pharm Sci; 2018 Mar; 114():55-63. PubMed ID: 29223619
[TBL] [Abstract][Full Text] [Related]
3. Anti-proliferative actions of N'-desmethylsorafenib in human breast cancer cells.
Cui PH; Rawling T; Gillani TB; Bourget K; Wang XS; Zhou F; Murray M
Biochem Pharmacol; 2013 Aug; 86(3):419-27. PubMed ID: 23732299
[TBL] [Abstract][Full Text] [Related]
4. Role of human CYP3A4 in the biotransformation of sorafenib to its major oxidized metabolites.
Ghassabian S; Rawling T; Zhou F; Doddareddy MR; Tattam BN; Hibbs DE; Edwards RJ; Cui PH; Murray M
Biochem Pharmacol; 2012 Jul; 84(2):215-23. PubMed ID: 22513143
[TBL] [Abstract][Full Text] [Related]
5. The impact of individual human cytochrome P450 enzymes on oxidative metabolism of anticancer drug lenvatinib.
Vavrová K; Indra R; Pompach P; Heger Z; Hodek P
Biomed Pharmacother; 2022 Jan; 145():112391. PubMed ID: 34847475
[TBL] [Abstract][Full Text] [Related]
6. 1118-20, an indazole diarylurea compound, inhibits hepatocellular carcinoma HepG2 proliferation and tumour angiogenesis involving Wnt/β-catenin pathway and receptor tyrosine kinases.
Lu YY; Wang JJ; Zhang XK; Li WB; Guo XL
J Pharm Pharmacol; 2015 Oct; 67(10):1393-405. PubMed ID: 26076716
[TBL] [Abstract][Full Text] [Related]
7. Flavin monooxygenases, FMO1 and FMO3, not cytochrome P450 isoenzymes, contribute to metabolism of anti-tumour triazoloacridinone, C-1305, in liver microsomes and HepG2 cells.
Fedejko-Kap B; Niemira M; Radominska-Pandya A; Mazerska Z
Xenobiotica; 2011 Dec; 41(12):1044-55. PubMed ID: 21859392
[TBL] [Abstract][Full Text] [Related]
8. Biotransformation of 2,2',4,4'-tetrabromodiphenyl ether (BDE-47) by human liver microsomes: identification of cytochrome P450 2B6 as the major enzyme involved.
Erratico CA; Szeitz A; Bandiera SM
Chem Res Toxicol; 2013 May; 26(5):721-31. PubMed ID: 23537005
[TBL] [Abstract][Full Text] [Related]
9. Sorafenib inhibition of hepatic stellate cell proliferation in tumor microenvironment of hepatocellular carcinoma: a study of the sorafenib mechanisms.
Geng ZM; Jha RK; Li B; Chen C; Li WZ; Zheng JB; Wang L; Huanchen S
Cell Biochem Biophys; 2014 Jul; 69(3):717-24. PubMed ID: 24633454
[TBL] [Abstract][Full Text] [Related]
10. Identification of human cytochrome P450 enzymes involved in the hepatic and intestinal biotransformation of 20(S)-protopanaxadiol.
Chiu NT; Tomlinson Guns ES; Adomat H; Jia W; Deb S
Biopharm Drug Dispos; 2014 Mar; 35(2):104-18. PubMed ID: 24151189
[TBL] [Abstract][Full Text] [Related]
11. Sorafenib inhibits intracellular signaling pathways and induces cell cycle arrest and cell death in thyroid carcinoma cells irrespective of histological origin or BRAF mutational status.
Broecker-Preuss M; Müller S; Britten M; Worm K; Schmid KW; Mann K; Fuhrer D
BMC Cancer; 2015 Mar; 15():184. PubMed ID: 25879531
[TBL] [Abstract][Full Text] [Related]
12. Heparin-functionalized Pluronic nanoparticles to enhance the antitumor efficacy of sorafenib in gastric cancers.
Yang YC; Cai J; Yin J; Zhang J; Wang KL; Zhang ZT
Carbohydr Polym; 2016 Jan; 136():782-90. PubMed ID: 26572413
[TBL] [Abstract][Full Text] [Related]
13. Development of HepG2-derived cells expressing cytochrome P450s for assessing metabolism-associated drug-induced liver toxicity.
Xuan J; Chen S; Ning B; Tolleson WH; Guo L
Chem Biol Interact; 2016 Aug; 255():63-73. PubMed ID: 26477383
[TBL] [Abstract][Full Text] [Related]
14. An in vitro tool to assess cytochrome P450 drug biotransformation-dependent cytotoxicity in engineered HepG2 cells generated by using adenoviral vectors.
Lahoz A; Vilà MR; Fabre M; Miquel JM; Rivas M; Maines J; Castell JV; Gómez-Lechón MJ
Toxicol In Vitro; 2013 Jun; 27(4):1410-5. PubMed ID: 22910125
[TBL] [Abstract][Full Text] [Related]
15. Flavonoid-enriched apple fraction AF4 induces cell cycle arrest, DNA topoisomerase II inhibition, and apoptosis in human liver cancer HepG2 cells.
Sudan S; Rupasinghe HP
Nutr Cancer; 2014; 66(7):1237-46. PubMed ID: 25256427
[TBL] [Abstract][Full Text] [Related]
16. Enhanced inhibition of microsomal cytochrome P450 3A2 in rat liver during diltiazem biotransformation.
Murray M; Butler AM
J Pharmacol Exp Ther; 1996 Dec; 279(3):1447-52. PubMed ID: 8968370
[TBL] [Abstract][Full Text] [Related]
17. The role of hepatic cytochrome P450s in the cytotoxicity of dronedarone.
Chen S; Wu Q; Ning B; Bryant M; Guo L
Arch Toxicol; 2018 Jun; 92(6):1969-1981. PubMed ID: 29616291
[TBL] [Abstract][Full Text] [Related]
18. Mechanisms of mitochondrial toxicity of the kinase inhibitors ponatinib, regorafenib and sorafenib in human hepatic HepG2 cells.
Paech F; Mingard C; Grünig D; Abegg VF; Bouitbir J; Krähenbühl S
Toxicology; 2018 Feb; 395():34-44. PubMed ID: 29341879
[TBL] [Abstract][Full Text] [Related]
19. In vitro toxicological evaluation of NCS-382, a high-affinity antagonist of γ-hydroxybutyrate (GHB) binding.
Vogel KR; Ainslie GR; Roullet JB; McConnell A; Gibson KM
Toxicol In Vitro; 2017 Apr; 40():196-202. PubMed ID: 28119166
[TBL] [Abstract][Full Text] [Related]
20. Cytochrome P450-mediated metabolism of haloperidol and reduced haloperidol to pyridinium metabolites.
Avent KM; DeVoss JJ; Gillam EM
Chem Res Toxicol; 2006 Jul; 19(7):914-20. PubMed ID: 16841959
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
